Compare BioNano Genomics Inc (BNGO) vs T-Mobile Us Inc (TMUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs T-Mobile Us Inc — how do they compare? BioNano Genomics Inc trades at $1.24 (market cap $13.66M), while T-Mobile Us Inc trades at $177.2 (market cap $191.56B). The key difference: T-Mobile Us Inc is far larger — about 14023.4× BioNano Genomics Inc's market cap, and T-Mobile Us Inc pays a 2.28% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | TMUS | |
|---|---|---|
Market Cap | $13.66M | $191.56B |
Sector | Health | Media |
52-Week High | $4.92 | $259.01 |
52-Week Low | $1.06 | $167.65 |
Enterprise Value | $16.26M | $308.17B |
Dividend Yield | — | 2.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.
The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.
TMUS trades at $177.02, down 0.64% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong Q2 2026 earnings, beating EPS estimates with $2.99 actual vs. $2.59 expected, and raised its free cash flow outlook. Revenue growth remains robust, reaching $88.31 billion in 2025, though net income dipped slightly to $10.99 billion. Recent news includes the completion of an $2.9 billion spectrum sale to Grain Management and competitive concerns from SpaceX's Starlink Mobile expansion.
The outlook for TMUS is mixed; strong fundamentals and analyst bullishness with an $233.20 price target suggest upside, but technical bearishness and competitive threats from new entrants like SpaceX pose risks. Earnings momentum and dividend growth support long-term value, yet near-term volatility may persist due to market sentiment and industry disruption.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About T-Mobile Us Inc
Deutsche Telekom merged its T-Mobile USA unit with prepaid specialist MetroPCS in 2013, creating T-Mobile Us. Following the merger, the firm provided nationwide service in major markets but spottier coverage elsewhere. T-Mobile spent aggressively on low-frequency spectrum, well suited to broad coverage, and has substantially expanded its geographic footprint. This expansion, coupled with aggressive marketing and innovative offerings, produced rapid customer growth. With the Sprint acquisition, the firm's scale now roughly matches its larger rivals: T-Mobile now serves 71 million postpaid and 21 million prepaid phone customers, equal to around 30% of the U.S. retail wireless market. In addition, the firm provides wholesale service to resellers.
Read more on TMUS →
